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1. Introduction 
The early postoperative course and management can have a significant impact on the long-
term success of a kidney transplant recipient. Several factors affect long-term outcomes 
including the occurrence of delayed graft function (DGF), episodes of acute rejection (AR), 
surgical complications, and overwhelming infections, especially sepsis [1-3]. Certain 
medications, including calcineurin inhibitors (CNI), also have potential for nephrotoxic 
effects, which can later lead to transplant glomerulopathy [4]. Furthermore, recipient 
characteristics, such as sensitization status, and donor characteristics, such as donation after 
cardiac death (DCD) donors and expanded criteria donors (ECD) can all affect long-term 
outcomes [5]. Although basic postoperative surgical principles are applied, there are certain 
parameters that need to be closely monitored, especially as it pertains to fluid management, 
blood pressure control, and immunologic status. Early detection of graft dysfunction is 
paramount in determining reversibility from both medical and surgical complications. 
Recognizing the technical limitations during surgery can also help prevent potentially 
devastating mechanical complications. Thus, appropriate initial management and mitigation 
of various risk factors is extremely important in the long-term success of the kidney 
transplant patient. 
2. Surgical procedure 
Technical variations exist for kidney transplant, such as in the retroperitoneal exposure or 
implantation of the ureter, but the basic surgical procedure will be described in this section. 
The right iliac fossa has traditionally been described as the initial choice for implantation, 
but previous operations, quality of vessels, or other recipient factors may make the left side 
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more approachable. In the case of polycystic kidney disease, where the native kidneys need 
to be removed, a midline incision is made. 
2.1. Backtable kidney preparation 
The kidney is kept cold in an ice slush bath during the preparation, which involves 
dissecting the renal artery and vein from the surrounding tissue. The ureter is identified and 
retracted away so as to avoid injury when removing extraneous fat and tissue from the 
kidney and hilum. Attention must be directed to protecting the blood supply to the ureter 
by avoiding the so-called “golden triangle” at the inferior pole of the kidney. Multiple renal 
arteries may also require repair and a Carrel patch may or may not be preserved depending 
on the degree of aortic plaque seen. In the case of a right kidney, the renal vein may require 
lengthening, which can be accomplished by utilizing the attached IVC.  
2.2. Surgical exposure 
An oblique curvilinear incision is made in the right or left lower quadrant of the abdomen, 
extending from near the pubic symphysis to above the anterior superior iliac spine of the 
iliac crest. Muscle layers can be directly divided, lateral to the rectus sheath, or split along 
the fibers of the external and internal obliques and transversalis. The peritoneum is 
identified and retracted superiorly and medially to expose the retroperitoneum. Self-
retaining retractors can be placed to facilitate subsequent exposure of the psoas and iliac 
vessels.  
2.3. Operative procedure 
The common or external iliac artery and vein are identified and dissected. Lymphatics that 
course along the length of the vessels need to be meticulously tied or cauterized to prevent 
occurrence of lymphoceles. Vascular flow is controlled proximally and distally with 
vascular clamps and the kidney is brought into the surgical field. A venotomy is first made 
in the recipient iliac vein and an end-to-side anastomosis with the renal vein is created with 
5-0 or 6-0 monofilament non-absorbable suture. Similarly, an arteriotomy is then made and 
the arterial anastomosis is completed in an end-to-side fashion. The clamps are released 
sequentially, with the vein before the artery, and the kidney is perfused. Once hemostasis is 
attained, the urinary tract is reconstructed. The bladder, which should be irrigated with 
antibiotic solution prior to start of the procedure, can be filled by way of a three-way Foley 
catheter or instilled with the antibiotic solution at the start of the operation. The kidney is 
positioned in the retroperitoneum and an area on the bladder is identified for implantation 
of the ureter. The layers of the bladder are carefully dissected and a cystostomy is created. 
The transplant ureter is cut to length and the anastomosis is done with or without a stent 
using monofilament absorbable suture. One technique described for ureteroneocystostomy 
is the Lich-Gregoir technique, which involves an anastomosis between the ureteral and 
bladder mucosa with a myotomy closure over the ureter. The abdominal wall is then 
reapproximated and closed in layers. 
 
Surgical Management of the Kidney Transplant Recipient 81 
3. Early postoperative course 
3.1. Renal and fluid management 
The initial management of the kidney transplant recipient involves proper fluid 
management, focusing on volume status and electrolyte balance. Assessing volume status is 
multifaceted and includes monitoring urine output, central venous pressure, heart rate, and 
blood pressure. Attention to daily weights and total input-output tabulations can help 
dictate fluid management, especially regarding the use of diuretics postoperatively. A 
decrease in urine volume can result from hypovolemia, obstruction, acute tubular necrosis 
(ATN), urinary leak, or in the most severe case, vascular thrombosis.  
Recipients of living donor kidney transplants have brisk urine output immediately or within 
minutes of implantation. Fluids may need to be replaced adequately to avoid a negative 
fluid balance within the first 24 hours. This can potentially compromise blood flow to the 
new kidney. Deceased donor allografts, in comparison, not make significant urine amounts 
initially. Fluid and furosemide challenges should be considered; however, if there has been 
little to no response after several attempts, then fluids should be administered judiciously in 
consideration of overall volume status from a respiratory, cardiovascular, and renal 
standpoint. The goal of fluid resuscitation in the early postoperative period focuses on 
maintaining good perfusion to the transplanted allograft. 
Changes in urine output should be assessed in an objective and systematic manner. First, the 
foley should be assessed for patency and flushed, as patients may have mild hematuria 
leading to clot formation. If hypovolemia is suspected, then a fluid challenge with 
crystalloid or albumin should be administered [6]. Failure to respond to a fluid challenge 
and increases in serum creatinine should prompt assessment of the graft with Duplex 
ultrasonography (DUS), which can be used to assess perfusion to the allograft, rule out 
hydronephrosis and evaluate perinephric fluid collections. Significant, but less dramatic 
decreases in urine output should raise clinical suspicion for renal artery or vein thrombosis, 
which would warrant surgical re-exploration if caught in a timely fashion. Patients with 
little to no response to fluid challenges should also be administered a furosemide challenge. 
Patients who fail to respond to fluid or furosemide without any structural or vascular 
abnormalities on DUS may have ATN, which can be confirmed with a biopsy. 
3.2. Cardiovascular and pulmonary assessment 
Assessment and maintenance of adequate blood pressure control is imperative to the 
success of the kidney transplant. Because the transplanted kidney is an end-organ, it is 
susceptible to injury during episodes of hypotension, which can lead to ATN. Careful 
attention to the choice of induction therapy being administered, such as rabbit 
antithymocyte globulin (rATG), is important as the side effect profile includes fever, 
dyspnea, respiratory distress, and hypotension [7]. If other causes of respiratory distress or 
hypotension have been excluded, the rate of rATG administration may need to be slowed or 
even stopped temporarily or permanently. Basiliximab, an interleukin-2 receptor antagonist 
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(IL2RA), has fewer side effects and can be administered as an alternative under different 
immunosuppression protocols. 
The use of calcium channel blockers has been shown to be beneficial in kidney 
transplantation. Intra-arterial administration of calcium channel blockers, such as verapamil, 
improves renal blood flow as well as augments immunosuppression [8]. Postoperative 
administration of oral calcium channel blockers has also been implemented, as there is 
evidence that the incidence of DGF is decreased [9]. In a large systematic review and meta-
analysis of randomized controlled trials, the use of calcium channel blockers has been 
shown to decrease the risk of graft loss and improved post-transplant glomerular filtration 
rates (GFR) [10]. Furthermore, in the early transplant period, the use of calcium channel 
blockers have been shown to be superior to angiotensin-converting enzyme inhibitors with 
regards to avoiding nephrotoxicity, improving GFR, improving hemoglobin levels, 
minimizing the incidence of hyperkalemia, and minimizing proteinuria post-transplant [10]. 
Respiratory complications can lead to poor outcomes. As previously stated, the use of rATG 
may lead to respiratory distress as capillary leak can occur. Acute respiratory failure post-
transplant can compromise allograft outcomes [11,12]. The leading cause of respiratory 
failure is typically bacterial pneumonia [12]. Patients with prolonged intensive care 
hospitalizations are at risk of invasive fungal and opportunistic infections, especially in the 
setting of intense perioperative immunosuppression. These infections have been linked to 
increased mortality [13]. Appropriate chemoprophylaxis with trimethoprim-
sulfamethoxazole for Pneumocystis jiroveci pneumonia may be beneficial and potentially 
mitigate the infectious risks [14]. 
4. Assessment of graft function 
4.1. Early graft dysfunction 
Early complications leading to graft dysfunction can be separated into two categories: 
medical or surgical.  Marginal donors, including ECD and DCD allografts, have the highest 
rate of medical and surgical complications [15,16]. Various medical and surgical 
complications resulting in early graft dysfunction are listed in Table 1. The following 
sections will discuss the most common culprits in each category. Hypovolemia has been 
discussed in a previous section. 
4.2. Primary non-function 
Primary non-function (PNF), defined as the lack of adequate allograft function by the third 
month post transplant, has a reported incidence between 1-8% [17-19]. Typically, patients at 
risk of PNF include highly sensitized patients and those on renal replacement therapy for a 
prolonged duration of time prior to transplantation. Acute rejection and surgical 
complications are the most common causes of PNF [19]. The use of histidine-tryptophan-
ketoglutarate (HTK) solution has also been implicated as a cause of PNF in deceased donor 
renal transplants [17]. A recent study suggests that a mean arterial blood pressure less than 
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or equal to 80 mm Hg approximately 3 months before kidney transplantation is a risk factor 
for PNF [18]. Certain donor factors, such as prolonged cold ischemia time, have also been 
associated with PNF [20]. Patients with PNF have poorer overall patient survival, compared 
to patients with immediate graft function, probably as a result of returning to renal 
replacement therapy at an earlier time. 
 
Common Causes of Early Graft Dysfunction
Medical Surgical
Delayed graft function Hemorrhage 
Hypovolemia Urinary obstruction 
Acute rejection Vascular thrombosis 
Drug-induced nephrotoxicity Hematuria 
Infection Arterial stenosis 
Disease recurrence Extrinsic obstruction 
Table 1. Common causes of early graft dysfunction stratified by medical or surgical causes. 
4.3. Immunologic events 
4.3.1. Hyperacute rejection 
Hyperacute rejection occurs in the setting of ABO incompatible transplants or in the setting 
of a positive lymphocytotoxic crossmatch, where the incidence is approximately 85%. Some 
antibodies may have lower binding affinity to receptors or fail to bind any complement. 
Once this process has occurred, treatment involves immediate removal of the allograft. 
Some protocols utilizing plasmapheresis have been used with modest results [21], but graft 
survival remains poor. The emergence of kidney-paired donation and chains has 
circumvented the need for transplantation across ABO blood groups [22]. Renal scan 
typically demonstrates no perfusion and pathology reveals microvascular thrombosis, thus 
necessitating a transplant nephrectomy. With the advent of modern immunologic testing 
prior to transplant, hyperacute rejection remains a rare occurrence. 
4.3.2. Accelerated vascular rejection 
Accelerated vascular rejection is an early aggressive form of acute rejection that may occur 
in sensitized recipients with a high panel-reactive antibody or patients with a previous 
transplant, despite a negative T cell crossmatch. This type of rejection occurs as early as 
postoperative day 2 or can be as late as postoperative day 5. Anti-rejection treatment 
modalities generally fail to be effective in these patients. Histology reveals fibrin deposition 
and endothelitis. These patients are typically treated similar to antibody-mediated rejection 
episodes with plasmapheresis, intravenous immunoglobulin, and/or antibody-depleting 
agents [23]. 
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4.3.3. Acute rejection 
Acute rejection can occur at any time in the early post-transplant period. The most common 
time point, however, is 5 to 7 days post-transplant. Acute cellular rejection remains the most 
common type of rejection episode. The incidence of acute rejection is highest in the first 6 
months post-transplant, with overall acute rejection rates between 10-20%. The immunologic 
profiles of the donor and recipient as well as the use of different immunosuppression 
protocols are important in stratifying acute rejection risk. Signs and symptoms of acute 
rejection include fever, elevated serum creatinine, increasing weight, and graft tenderness. 
Transplant biopsy remains the gold standard for diagnosis. Histological changes in acute 
rejection include tubulitis and interstitial infiltrates, with or without arteritis [24]. 
Treatment of acute cellular rejection depends on the severity. First-line therapy includes a 
steroid pulse. In more severe cases of acute rejection, an antibody-depleting agent, such as 
rATG should be administered in addition to a steroid pulse. CNI levels should be monitored 
closely in the setting of acute rejection, as nephrotoxicity is more common. Moreover, in the 
setting of antibody-depleting therapy, patients should be monitored closely for infectious 
complications [25]. Graft survival is negatively impacted by episodes of acute rejection [26]. 
5. Technical complications 
5.1. Vascular 
5.1.1. Renal artery thrombosis 
Renal artery thrombosis is a rare event. Technical issues, such as arterial kinking or intimal 
dissection, are the usual culprits. The majority of these events occur in the first few days 
following transplantation. Sudden cessation of urine production should raise the suspicion 
for vascular compromise. Risk factors for this devastating condition include the use of 
pediatric donors less than or equal to 15 kg without an aortic patch as well as kidneys from 
donors less than 5 years of age [27,28]. However, use of pediatric donors less than 10 kg has 
also been successfully reported without an increased rate of arterial thrombosis [29]. The 
diagnosis must be made promptly, as the allograft can only tolerate 30-60 minutes of warm 
ischemia before the allograft has irreversible injury. Even in ideal situations, recovery from 
ischemic injury may still be impossible. A high-index of suspicion is necessary to ensure 
prompt and adequate treatment of this condition with emergent re-operation. In cases where 
the recipient had previously made urine at baseline, the diagnosis becomes even more 
difficult. The diagnosis is made with DUS, which demonstrate lack of color flow (Figure 1). 
When multiple renal arteries are present on the donor allograft, reconstruction may be 
necessary during implantation. Most authors have reported no difference in vascular 
complications or graft survival [30]. However, thrombosis of some minor branches supplying 
superior or inferior poles can lead to partial infarction of the renal allograft. Patients may 
present with elevated serum creatinine or hypertension. Subsequent angiogram will 
demonstrate a wedge perfusion defect of the allograft. Patients may then present with urine 
leak if caliceal infarction is present. In such circumstances, the patient may benefit from 
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nephrostomy tube placement for complete urinary decompression as well as percutaneous 
drain placement in the event of urinoma development. 
 
Figure 1. Doppler ultrasound demonstrates global hypoperfusion of the transplanted kidney consistent 
with renal artery thrombosis on postoperative day 1. 
5.1.2. Renal vein thrombosis 
Renal vein thrombosis is also an uncommon, but potentially devastating, complication. The 
usual causes include injuries to the donor renal vein that was narrowed after repair of an 
injury or twisting of the vein on the renal pedicle. Previously, the use of right-sided living 
donor renal allografts was associated with an increased risk of renal vein thrombosis due to 
the short length. However, we have not seen this in our large series of right-sided donors, 
even with modern procurement techniques, such as laparoendoscopic single-site surgery 
[31,32]. Patients present with gross hematuria, decreased urine output and engorgement of 
the graft due to venous outflow obstruction. DUS will show parvus tardus and reversal of 
diastolic flow in the renal artery. Immediate repair is necessary if there is to be any chance of 
salvaging the allograft. 
5.1.3. Hemorrhage and hematoma 
Most postoperative hematomas are small and insignificant. They are usually incidentally 
found on a post-transplant DUS. Larger and more clinically significant hematomas may 
occur in the setting of antiplatelet therapy or anticoagulation for patients with risk factors 
for venothromboembolic events (Figure 2). Patients with clinically significant hematomas 
will present with swelling from the incision, pain over the graft, and an acute drop in 
hemoglobin values. The hematoma will continue to increase in size until it ultimately 
impinges on the vascular pedicle of the allograft, which can lead to thrombosis or 
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hydronephrosis. Postoperatively, patients may show signs of bruising in dependent regions 
of the wound, flank and groin. 
 
Figure 2. Panel A demonstrates an early postoperative hematoma (as outlined by plus signs) above the 
fascia in a transplant patient on systemic anticoagulation. Panel B illustrates a perinephric hematoma 
(as outlined by plus signs) in the same patient. 
Patients requiring postoperative anticoagulation for prophylaxis of a vascular thrombotic 
event are at greatest risk of developing a hematoma [33,34]. The reported risk of a 
postoperative bleed on heparin requiring surgical exploration has been reported as high as 
60% in patients on anticoagulation. Moreover, patients with a history of lupus and lupus 
anticoagulant are especially sensitive to heparin anticoagulation, leading to an increased 
risk of postoperative hemorrhage [35]. Percutaneous drainage of large hematomas is 
insufficient and operative exploration and evacuation should be undertaken to avoid 
vascular thrombosis and to remove clot as a potential nidus of infection. 
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5.1.4. Renal artery stenosis 
Transplant renal artery stenosis is a late complication of kidney transplantation. The diagnosis 
is usually made with DUS, which demonstrates parvus tardus waveforms as well as elevated 
resistive indices. An MRA is necessary to confirm the diagnosis. Treatment includes 
interventional procedures involving balloon angioplasty and potentially stenting or surgical 
repair with cadaveric graft. This topic is discussed in detail in another chapter of this textbook. 
5.2. Urinary 
5.2.1. Ureteral obstruction 
Pelvicaliceal dilation seen on DUS implies obstruction in the urinary flow. Placement of a 
foley catheter and examination of its patency can provide relief if the cause is from an 
enlarged prostate or dysfunctional bladder. Failure of the foley catheter to relieve 
obstruction necessitates immediate decompression via placement of a percutaneous 
nephrostomy tube. An antegrade pyelogram can be performed to visualize where the 
obstruction occurs (Figure 3). A decrease in the serum creatinine following decompression 
confirms the diagnosis. After 1-2 days of allowing the postoperative edema to subside, a 
nephrogram is performed to evaluate whether ureteral obstruction or stenosis remains. 
Early strictures usually require surgical repair, where as late strictures are more amenable to 
less invasive procedures, such as stent placement and angioplasty. 
 
Figure 3. An antegrade pyelogram is shown demonstrating complete obstruction (red arrow) at the 
ureteroneocystostomy anastomosis of the transplanted kidney in the right lower quadrant. 
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Ureteral strictures in the early postoperative period are related to technical issues. Patients 
with ureteral stents will not present with obstruction in the early postoperative period. Rather 
they may present with this problem several weeks after stent removal. This complication is 
usually the result of a twist in the ureter or narrowing at the anastomosis due to distal ureteral 
ischemia [36]. Short segment strictures (< 2 cm) are usually amenable to percutaneous 
dilatation whereas longer strictures (>2 cm) and those involving the proximal or mid-ureter 
typically require surgical revision. The treatment options include excising the stricture and 
creating a new ureteroneocystostomy, if sufficient length is available on the transplant ureter. 
A psoas hitch or Boari flap can be performed to bring the bladder closer to the kidney to assist 
in this approach. Otherwise, a ureteroureterostomy using the ipsilateral native ureter or 
ureteropyelostomy may be required. A 6 French double-J stent can be left in place for 4 to 6 
weeks. In cases where the ipsilateral native ureter is unavailable, the contralateral ureter can 
also be used. Graft survival is not significantly affected in patients undergoing correction or 
revision of urologic complications in the first year post-transplant [37].  
5.2.2. Urine leak 
Urine leak usually occurs in the first month after transplant and is due to a disruption in the 
ureteral-bladder anastomosis. Caliceal infarction from a partial thrombosis of the renal 
allograft can also present as a urine leak. The presenting symptoms include abdominal pain, 
increasing serum creatinine level and a decrease in urine output. Typically, a DUS or renal 
scan shows a fluid collection in the retroperitoneal space (Figure 4). Sampling of the fluid 
and analysis for creatinine can confirm the diagnosis of a urinoma.  
 
Figure 4. Urinoma (yellow arrow) located at the inferior pole of the transplanted kidney as a result of a 
urine leak. 
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Causes of urine leak include technical issues related to creation of the ureteroneocystostomy 
or ischemic necrosis of the distal ureter. Urgent surgical management of this condition is 
mandatory to decrease the risk of wound infection and improve potential for recovery of the 
allograft.  
5.3. Lymphocele 
A lymphocele is a collection of lymphatic fluid that develops in the postoperative field in a 
nonepithelialized cavity. These collections typically form around the divided lymphatics 
surrounding the recipient iliac vasculature. Most lymphoceles are asymptomatic and do not 
require any intervention; however, lymphoceles can cause compressive symptoms from 
mass effect on surrounding tissue and structures, or can become infected. Most lymphoceles 
occur between 2 weeks and 6 months post-transplant [38]. The peak incidence is about 6 
weeks post-transplant. The source of the lymphocele is from disrupted lymphatic channels 
surrounding the iliac vasculature during implantation. Lymphocele formation can be 
prevented by meticulous dissection and ligation of all lymphatic trunks with a 
nonabsorbable suture. Some have even suggested that lymphocele formation can be avoided 
by anastomosing to the common iliac vasculature were less lymphatic tissue is present [39]. 
The use of mTOR inhibitors has been strongly and positively correlated with the 
development of lymphoceles in kidney transplantation [40].  
 
Figure 5. A lymphocele (white arrow) can be seen on CT scan compressing the right lower quadrant 
transplanted kidney (red arrow) causing hydronephrosis. 
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Lymphoceles are suggested by DUS or CT scan findings demonstrating a large fluid 
periallograft collection (Figure 5). The most common location is adjacent to the bladder and 
multiple collections may be present. Sending aspirated fluid for cytological and biochemical 
analysis for lymphocytes can confirm the diagnosis. Small, asymptomatic collections should 
be left alone, as spontaneous resolution is common. Larger collections and those that are 
causing obstructive symptoms can be initially managed by placement of a percutaneous 
drain. Recurrence is common and several aspirations may be necessary. Each aspiration 
carries a theoretical risk of infection. Sclerotherapy with povidone-iodine can be effective 
[41]. A possible complication of povidone-iodine is acute renal failure and this should be 
monitored during and after treatment [42]. Operative drainage of lymphoceles provides 
definitive therapy. The goal for drainage is to allow communication with the peritoneal 
cavity where it can be reabsorbed. This can be done via an open or the preferred 
laparoscopic approach [38]. The lymphocele is unroofed or fenestrated with a 5 cm opening 
to allow direct drainage into the peritoneal cavity.  
6. Medical complications 
6.1. Delayed graft function 
Delayed graft function (DGF) is the most common cause of early graft dysfunction and is 
defined as the need for dialysis within the first week after transplant. DGF has been 
reported to affect approximately 20-25% of all deceased donor transplant recipients [43]. 
Recipients of marginal donors, including ECD and DCD, have rates of DGF as high as 70% 
in some studies [15, 44]. The use of pulsatile hypothermic machine perfusion has been 
shown in studies to reduce that risk, though the overall rate still remains higher than SCD 
allografts [44]. Various donor risk factors for DGF include age, cause of death, and ischemia 
reperfusion injury [45]. 
DGF is a well-documented risk factor for poor graft survival. In a 2011 study analyzing 40 
years of deceased donor renal transplant recipients, the occurrence of DGF and acute 
rejection were the most significant predictors of renal allograft survival rates [26]. As 
previously discussed, marginal donors have the highest rates of DGF, while the rate of DGF 
in living donors is relatively uncommon. Additionally, patients undergoing 
retransplantation have higher rates of DGF than first time recipients of renal allografts. ECD 
allograft recipients may have a higher rate of acute rejection, which may be related to the 
higher rate of DGF in these allografts [46]. Prolonged cold ischemia has been a well-
documented cause of DGF; however, recent data suggests that cold ischemia-induced DGF 
may play a limited role in long-term outcomes [47]. 
The use of DUS and biopsy can differentiate DGF from other causes of early graft 
dysfunction, such as acute rejection or surgical complications. A transplant biopsy is usually 
necessary to differentiate between other causal factors, such as acute rejection or recurrent 
disease. Radiographic studies in the proper clinical context can also aid in the diagnosis of 
DGF. Typically, transplants with DGF will demonstrate good renal perfusion and good 
parenchymal uptake of radionucleotide tracer with little or no renal excretion. Primary non-
function should be considered in the differential at this time point. 
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6.2. Drug-induced nephrotoxicity 
Calcineurin inhibitors (CNIs) have become the cornerstone of immunosuppression 
regimens. Early administration post-transplant has helped mitigate the risk of acute 
rejection in kidney transplantation. Most institutions have implemented the use of 
polyclonal antibody-depleting or monoclonal antibody induction therapy in conjunction 
with introduction of CNIs as early as postoperative day 1 or 2, as we do in our institution. 
CNIs can have a nephrotoxic effect on the allograft by decreasing renal blood flow in the 
afferent arteriole, leading to tubular injury [48]. Variable oral absorption of CNIs, especially 
cyclosporine, in the early postoperative period can lead to either overdosing or 
underdosing, causing either nephrotoxicity or acute rejection, respectively.  
Differentiating calcineurin inhibitor toxicity from other causes of graft dysfunction is 
difficult based on clinical context. Percutaneous transplant biopsy can be used to diagnose 
other causes of graft dysfunction. Histologic findings are non-specific with tubular injury 
and tubular vacuolization being the most common early findings. Hyaline deposition and 
fibrosis can be found with chronic injury. Obtaining daily calcineurin inhibitor levels can 
prevent supratherapeutic dosing, predisposing patients to the nephrotoxic effects. Avoiding 
nephrotoxicity is important, as chronic nephrotoxicity has been shown to correlate with 
chronic transplant nephropathy, ultimately affecting long-term allograft survival [49]. 
6.3. Infectious complications 
Infectious complications in the early postoperative period are typically related to the 
operation. The most common postoperative infections include surgical site infections, 
urinary tract infections, bacteremia from central venous catheters, and pneumonia [50]. 
Careful and meticulous surgical technique and attention to detail can help prevent most 
early infectious complications, such as surgical site infections, central venous catheter sepsis, 
and urinary tract infections from foley catheter placement. Encouraging early ambulation 
and the use of incentive spirometry decreases the incidence of atelectasis and the risk of 
postoperative pneumonia. Removing foley catheters and stents once they no longer serve an 
appreciable purpose can help prevent and eliminate urinary tract infections. Central venous 
catheters should be removed as early as possible to decrease the incidence of line sepsis. 
Typically, opportunistic infections are relatively uncommon in the early postoperative 
period (<30 days). Cytomegalovirus (CMV) infection occurs, especially in seronegative 
recipients receiving allografts from seropositive donors. Institution of CMV prophylaxis 
with oral valganciclovir or high-dose oral acyclovir for a minimum of 3 months has 
significantly reduced the incidence and severity of CMV infection [51]. Once antiviral 
prophylaxis has been halted, CMV infection may still occur. Appropriate prophylaxis with 
trimethoprim/sulfamethoxazole has almost entirely eliminated early Pneumocystis carinii 
pneumonia. Prophylactic antifungal agents, such as nystatin or clotrimazole troches, have also 
been instituted to decrease the risk of oral Candida infections in the early postoperative period. 
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Prompt diagnosis and treatment of infectious complications leads to better outcomes. 
Aggressive treatment with intravenous antibacterial, antiviral or antifungal agents for 
severe infections improve outcomes. Infected intra-abdominal collections should be drained. 
Minimizing external instrumentation should be part of the fundamental strategy in 
preventing infectious complications. 
6.4. Disease recurrence 
The majority of causes of end-stage renal disease (ESRD) do not recur early in the post-
transplant period. Disease processes such as diabetes mellitus and hypertension can cause 
recurrence of ESRD if poorly controlled over a long period of time. Two causes of ESRD, 
however, can recur immediately post-transplant: focal segmental glomerulosclerosis (FSGS) 
and thrombotic microangiopathy (TMA). 
FSGS is a form of glomerulonephritis that can recur immediately post-transplant. Although 
the exact mechanism is unclear, a serum factor causes glomerular injury and early massive 
proteinuria [52,53]. The development of nephrotic range proteinuria can be suggestive of 
disease recurrence in a patient with a pretransplant diagnosis of FSGS. The diagnosis can be 
verified with electron microscopy demonstrating effacement of foot processes. Current 
treatment strategies include increasing calcineurin inhibitor dosing, steroids, and 
plasmapheresis, with the latter modality being the most effective [52]. If patients fail to 
respond over several weeks, then further treatments are not likely to be effective. 
Thrombotic microangiopathy can also recur relatively quickly post-transplant. Causes of 
TMA include recurrent disease, endothelial damage from calcineurin inhibitor use, 
hypercoagulable disorders, or antibody-mediated rejection episodes [54]. Clinical 
manifestations include hemolysis and decreases in hemoglobin, platelet count, and 
haptoglobin. Additionally, microangiopathy will be present on peripheral blood smears. 
Patients will have increases in lactate dehydrogenase and serum creatinine, signifying 
allograft dysfunction. Transplant biopsy will show fibrin clot in arterioles. Treatment 
includes removing inciting factors, such as calcineurin inhibitors, as well as plasmapheresis 
[55]. Eculizumab, a humanized monoclonal antibody to complement component 5 (C5) to 
mediate complement-mediated injury, has emerged as a possible treatment option for TMA 
[56]. Blocking complement activation, especially the last step of the complement cascade, 
has important implications in TMA. Treatment of TMA posttransplant has been successfully 
reported [57], but still carries a poor prognosis. 
7. Summary 
Early management of the kidney transplant recipient is crucial for optimizing outcomes and 
avoiding early graft loss, or even death. Given the surgical and medical complexity of these 
patients, attention to detail and prompt diagnosis of complications is critical to achieving 
excellent outcomes. Clinical scenarios need to be recognized where early operative 
intervention is necessary to save the graft. However, whenever possible, prevention of 
complications provides the best outcomes.  
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